Drugs that contain Ganaxolone
1. List of Ztalmy drug patents
| Patent Number | Company | Patent Title | Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US8318714 | MARINUS | Liquid ganaxolone formulations and methods for the making and use thereof |
Nov, 2026
(3 years from now) | |
| US8618087 | MARINUS | Solid ganaxolone formulations and methods for the making and use thereof |
Nov, 2026
(3 years from now) | |
| US9056116 | MARINUS | Liquid ganaxolone formulations and methods for the making and use thereof |
Nov, 2026
(3 years from now) | |
| US8367651 | MARINUS | Solid ganaxolone formulations and methods for the making and use thereof |
Nov, 2026
(3 years from now) | |
| US9029355 | MARINUS | Solid ganaxolone compositions and methods for the making and use thereof |
Nov, 2026
(3 years from now) | |
| US8022054 | MARINUS | Liquid ganaxolone formulations and methods for the making and use thereof |
Nov, 2026
(3 years from now) | |
| US7858609 | MARINUS | Solid ganaxolone formulations and methods for the making and use thereof |
Nov, 2026
(3 years from now) | |
| US10603308 | MARINUS | Methods and compositions for treatment of epileptic disorders |
Aug, 2037
(14 years from now) | |
| Exclusivity | Exclusivity Expiration |
|---|---|
| New Chemical Entity Exclusivity (NCE) | Jun 1, 2027 |
| Orphan Drug Exclusivity (ODE) | Jun 1, 2029 |
NCE-1 date: 2026-06-01
Market Authorisation Date: 01 June, 2022
Treatment: Treatment of seizures associated with cyclin-dependent kinase-like 5 (cdkl5) deficiency disorder (cdd) in patients 2 years of age and older
Dosage: SUSPENSION;ORAL
More Information on Dosage
ZTALMY family patents
28
United States
4
Korea, Republic of
4
Japan
3
Mexico
3
China
3
European Union
2
Israel
2
Australia
2
Canada
1
Colombia
1
New Zealand
1
AP
1
EA
1
Spain
1
Brazil
900+ leading pharmaceutical companies are staying up-to-date with drug patents through Pharsight
Join them to stay ahead in capturing the next drug going generic